Group 1 - The company has submitted an application for issuing H shares to the Hong Kong Stock Exchange, with the relevant filing materials accepted by the China Securities Regulatory Commission [1] - In the large chemical sector, the company aims to enhance its profitability by extending its upstream and downstream industrial chain, including several strategic investment projects in polystyrene production [1] - The company plans to actively promote the recovery of production capacity at Guoen Chemical (Dongming) and integrate internal resources to establish a complete vertical industrial chain from monomers to end products [1] Group 2 - In the health sector, the company is focusing on the "collagen+" strategy, with its subsidiary Dongbao Biological leading in the collagen field and expanding its hollow capsule production capacity [2] - Dongbao Biological has an annual production capacity of 13,500 tons of gelatin, while Yiqing Biological has a capacity of 39 billion hollow capsules, which is expected to increase significantly after the completion of its new production project [2] - The company anticipates a significant increase in performance due to the expansion of hollow capsule production capacity, entering a growth phase [2] Group 3 - The company expects to achieve net profits of 742 million, 947 million, and 1.095 billion yuan from 2025 to 2027, with corresponding price-to-earnings ratios of 12.57X, 9.84X, and 8.52X, respectively [2]

Core Viewpoint - Guoen Technology Co., Ltd. officially listed on the Hong Kong Stock Exchange on February 4, with an initial offering price of HKD 36 per share, opening at HKD 45, a 25% increase, and a total market capitalization of approximately HKD 135 billion [1] Company Overview - Guoen Technology specializes in new chemical materials and upstream and downstream products of gelatin and collagen, serving the chemical and health industries [4][5] - The company was founded in 2000 by Wang Aiguo in Qingdao and has developed into a vertically integrated industrial cluster over more than 20 years [5][7] Financial Performance - Revenue projections for Guoen Technology are as follows: RMB 134 billion for 2022, RMB 174.4 billion for 2023, and RMB 191.9 billion for 2024, with net profits of RMB 7.2 billion, RMB 5.4 billion, and RMB 7.2 billion respectively [5][6] - For the first three quarters of 2025, the company reported revenue of RMB 154.97 billion and a net profit of RMB 7.21 billion [5] Business Segments - The company operates in two main segments: the large chemical segment, which accounts for approximately 95.6% of revenue, and the large health segment, which accounts for about 4.4% [6][7] - In the large chemical sector, Guoen Technology has established three main business engines: green petrochemical new materials, organic polymer modified materials, and organic polymer composite materials [7] IPO Details - The IPO saw a subscription rate of 2,251.85 times for the public offering, with 300,000 shares allocated, representing 10% of the total offering [4] - The international placement received a subscription rate of 10.03 times, with 27 million shares allocated, accounting for 90% of the total offering [4] Future Plans - Proceeds from the IPO will be used to establish a new production base in Thailand to expand capacity, produce organic polymer modified materials, and set up a regional headquarters to support international market expansion [8]

Core Viewpoint - Guoen Co., Ltd. is advancing its internationalization strategy by issuing H-shares at a price of HKD 36.00 per share, set to be listed on February 4, 2026, on the Hong Kong Stock Exchange, aiming to enhance its capital operation platform and support the dual circulation strategy in China [2]. Group 1: Company Overview - Guoen Co., Ltd. was established in 2000 and focuses on two core industries: large-scale chemicals and health [3]. - The company was listed on the Shenzhen Stock Exchange in 2015 [3]. Group 2: Health Sector - In the health sector, Guoen holds a controlling stake in Dongbao Biological, which specializes in collagen products, including gelatin, blood plasma gelatin, collagen protein, and beauty products, with applications in medicine, beauty, health, and food [4]. Group 3: Chemical Sector - In the chemical sector, Guoen has developed a cluster of new chemical materials, including green petrochemicals, organic polymer modifications, and biodegradable materials, establishing long-term partnerships with major clients like Hisense, Gree, TCL, Huawei, BOE, and CATL [5]. - The company has announced a new project for producing 20,000 square meters of aviation-grade acrylic glass, with an investment of CNY 560 million, aimed at becoming a key supplier of aviation transparent materials in China [6]. Group 4: Production Capacity - Current production capacities include: - Organic polymer modification: 1.08 million tons, with 300,000 tons under construction - Organic polymer composite materials: 400,000 tons, with 100,000 tons under construction - Green petrochemical materials: 900,000 tons, with 1.02 million tons under construction - Polystyrene (PS): 600,000 tons per year from the first phase of a project, with a second phase of 400,000 tons underway [7][8]. Group 5: Financial Performance - In 2024, Guoen achieved a total revenue of CNY 19.22 billion, a year-on-year increase of 10.21%, with a net profit of CNY 676 million, up 45.18% [9]. - For the first three quarters of 2025, the company reported total revenue of CNY 15.497 billion, a 9.44% increase year-on-year, and a net profit of CNY 615 million, up 34.24% [10].

Core Viewpoint - Guoen Technology is set to launch its global offering on January 27, with a pricing range of HKD 34-42 per share, aiming for a total issuance scale of approximately HKD 10.2 billion to 12.6 billion. The market is discussing the rationality of its pricing, stock price stability post-listing, and long-term valuation logic due to various factors including its business structure and competitive landscape [1][4][11]. Group 1: Financial Performance - Guoen Technology's revenue for 2022-2024 is projected at CNY 134 billion, CNY 174 billion, and CNY 192 billion, with a compound annual growth rate (CAGR) of 19.6%. However, growth is expected to slow to 9.9% in the first ten months of 2025 [2][3]. - The company's net profit has shown significant volatility, with figures of CNY 6.6 billion, CNY 4.7 billion, CNY 6.9 billion, and CNY 7.1 billion for the same periods, reflecting fluctuations of 3.1%, -29.7%, 45.2%, and 40.2% respectively [2][3]. Group 2: Cost Structure and Profitability - Raw material costs account for over 90% of sales costs, leading to limited profitability. The gross margin has declined from 11.8% to 8.3% from 2022 to 2024, with a slight recovery to 10.4% in the first three quarters of 2025 [3][11]. - The health sector shows stronger profitability potential, with a gross margin of 22.5% in the first ten months of 2025, but its revenue contribution is only 3.5%, insufficient to offset the low margins from the chemical sector [3][11]. Group 3: Market Position and Investor Interest - Guoen Technology's market capitalization of CNY 151 billion is the smallest among five concurrent A to H projects, which may reduce its attractiveness to institutional investors [4][5]. - The company has attracted eight cornerstone investors, raising USD 4.1 million, with significant investments from local and health-focused entities, indicating a strategic interest in its health sector [6][8]. Group 4: Market Dynamics and Risks - The absence of a greenshoe option in the offering raises concerns about stock price stability post-listing, as it lacks market support mechanisms [9][10]. - The Hong Kong market's preference for high-growth sectors may limit Guoen Technology's valuation, as its chemical business faces inherent valuation discounts compared to high-margin sectors [11].

Group 1 - The core viewpoint of the news is that Guoen Technology, a Chinese chemical materials supplier, has successfully completed its IPO subscription, raising significant interest from investors with an oversubscription rate of 878 times [1] - Guoen Technology plans to issue 30 million H-shares, with 10% allocated for Hong Kong and 90% for international offerings, and has a total fundraising target of up to 1.26 billion HKD [1] - The company has attracted eight cornerstone investors, raising a total of approximately 320 million HKD [1] Group 2 - Guoen Technology, founded in 2000, specializes in chemical new materials and gelatin, serving both the chemical and health industries [2] - The company is the second-largest producer of bone gelatin in China and the largest domestic brand, as well as the second-largest domestic brand in the hollow capsule industry, according to Frost & Sullivan [2] - Financially, the company reported revenues of approximately 13.406 billion RMB, 17.439 billion RMB, 19.188 billion RMB, and 17.444 billion RMB for the fiscal years 2022, 2023, 2024, and the first ten months of 2025, respectively [2] Group 3 - The net proceeds from the IPO are expected to be approximately 1.058 billion HKD, with 50% allocated to expanding production capacity in Thailand, 35% for new production capacity in China, 10% for investments in Hong Kong, and 5% for operational funds [3]

Group 1 - The core viewpoint of the article is that Guoen Technology, a Chinese chemical materials supplier, has successfully completed its IPO subscription, raising significant interest from investors with an oversubscription of 878 times the public offering amount [1] - Guoen Technology plans to issue 30 million H-shares, with 10% allocated for Hong Kong and 90% for international offerings, and a total fundraising target of up to HKD 1.26 billion [1] - The company has attracted eight cornerstone investors, with a total subscription amount of approximately HKD 320 million [1] Group 2 - Guoen Technology, founded in 2000, specializes in chemical new materials and gelatin, serving both the chemical and health industries [2] - The company is the second-largest producer of bone gelatin in China and the largest domestic brand in terms of production volume, as well as the second-largest domestic brand in the hollow capsule industry [2] - Financially, the company reported revenues of approximately RMB 134.06 billion, RMB 174.39 billion, RMB 191.88 billion, and RMB 174.44 billion for the fiscal years 2022, 2023, 2024, and the first ten months of 2025, respectively [2] Group 3 - The net proceeds from the IPO are expected to be approximately HKD 1.058 billion, with 50% allocated to expanding production capacity in Thailand, 35% for new production capacity in China, 10% for investments in Hong Kong, and 5% for operational funds and general corporate purposes [3]

Investment Rating - The investment rating for the company is 5.5 out of 10, based on operational performance, industry outlook, valuation, and market sentiment [8]. Core Insights - The company is a leading supplier in China focused on chemical new materials and gelatin, with over 95% of its revenue coming from the large chemical sector. It ranks as the second-largest in organic polymer modified materials and organic polymer composite materials in China, holding a market share of 2.5% [1]. - The company has shown steady revenue growth, with projected revenues of approximately RMB 134.1 billion, 174.4 billion, and 191.9 billion for the years 2022, 2023, and 2024 respectively. In the first ten months of 2025, revenue reached RMB 174.4 billion, reflecting a year-on-year increase of 10% [1]. - The net profit attributable to shareholders for 2022, 2023, and 2024 was RMB 6.63 billion, 4.71 billion, and 6.85 billion respectively, with a significant increase of 40% year-on-year to RMB 7.12 billion in the first ten months of 2025 [1]. Company Overview - The company specializes in green petrochemical materials, including aromatic olefins, styrene, polystyrene, and organic polymer modified materials, which are applied in automotive, new energy, and home appliance sectors. It also operates in the health sector, producing gelatin, collagen, and hollow capsules [1]. - The global market for organic polymer modified materials and organic polymer composite materials is expected to grow at a compound annual growth rate (CAGR) of 12.6% from 2025 to 2029, with China projected to grow at 14.1% [2]. Advantages and Opportunities - The company has established a strong market position in the organic polymer modified materials sector through a vertically integrated model and strategic expansion into the health sector, creating a dual growth engine under its "one body, two wings" strategy [3]. - It has a robust research and development capability, a strong reputation, and long-term partnerships with leading enterprises, supported by a visionary and experienced management team [3].

Core Viewpoint - The Hong Kong IPO market is experiencing a surge in demand, with Guoen Technology Co., Ltd. (referred to as "Guoen") launching its H-share offering, indicating strong investor interest and confidence in the company's growth potential [1][4]. Group 1: IPO Details - Guoen's H-share offering consists of 30 million shares, with approximately 10% allocated for public sale in Hong Kong and 90% for international investors [1]. - The price range for the H-share issuance is set between HKD 34 and HKD 42, with the public offering portion exceeding HKD 3.3 billion and an oversubscription rate of nearly 30 times [1][4]. Group 2: Investor Confidence - The cornerstone investor lineup for Guoen's IPO includes prominent institutions such as Liguan Investment, SLD International, and Luminous Horizon, collectively planning to subscribe for approximately HKD 320 million of the offering [4][5]. - The backing from these institutional investors reflects a strong market perception of Guoen's long-term value and growth prospects [5]. Group 3: Company Strengths - Guoen is recognized as the second-largest producer of organic polymer modified materials and organic polymer composite materials in China, and the largest producer of polystyrene by capacity [7]. - The company serves major clients in the home appliance, automotive, and new energy sectors, including Hisense, Midea, BYD, and CATL [7]. - In the health sector, Guoen controls Dongbao Biological, covering the entire industrial chain from gelatin raw materials to hollow capsules, ranking second in bone gelatin production and second among domestic brands in hollow capsule production in China [7]. Group 4: Fund Utilization - Guoen plans to allocate approximately 50% of the raised funds to establish a new production base in Thailand to expand capacity, while 35% will be used to enhance the production capacity of its Yixing facility [9]. - This strategic expansion aligns with the trend of downstream industries, such as home appliances and automotive, moving overseas, thereby opening new growth opportunities for the company [9].

Core Viewpoint - Guoen Technology (02768.HK) plans to globally offer 30 million H-shares, with 3 million shares available in Hong Kong and 27 million shares for international distribution, aiming for a price range of HKD 34.00 to 42.00 per share, with trading expected to commence on February 4, 2026 [2][3] Company Overview - Guoen Technology specializes in chemical new materials and gelatin, collagen, and related products, serving both the chemical and health industries [3] - The company operates in two main sectors: the large chemical sector, providing solutions to manufacturers in automotive, new energy, and home appliances, and the health sector, supplying raw materials for supplements and pharmaceuticals [3][4] Market Position - In the large chemical industry, Guoen is the second-largest company in China for organic polymer modified materials and organic polymer composite materials, holding a market share of 2.5% as of 2024 [4] - Guoen is also the largest producer of polystyrene in China by production capacity as of 2024 [4] Financial Performance - The company has shown strong revenue growth, with revenues of RMB 13.406 billion, RMB 17.439 billion, and RMB 19.188 billion for the fiscal years 2022, 2023, and 2024 respectively, reflecting a compound annual growth rate (CAGR) of 19.6% from 2022 to 2024 [7] - The sales figures for the fiscal years 2023 and 2024 indicate year-on-year growth rates of 30.1% and 10.0%, respectively [7] Market Trends - The market for organic polymer modified materials and organic polymer composite materials is projected to grow from RMB 303.8 billion in 2020 to RMB 544.8 billion by 2024, with a CAGR of 15.7% [8] - The market is expected to continue strong growth, reaching RMB 1,037.5 billion by 2029, with a forecasted CAGR of 14.1% from 2025 to 2029 [8] Use of Proceeds - The net proceeds from the share offering are estimated at approximately HKD 1.057 billion, with plans to allocate 50% for establishing a new production base in Thailand, 35% for expanding capacity in Yixing, and 10% for investments in Hong Kong [9]

Group 1 - The core viewpoint of the news is that Guoen Technology (国恩科技) is preparing for its IPO in the Hong Kong market, with a strong foundation and significant fundraising expectations [2][4] - Guoen Technology plans to globally issue approximately 30 million H-shares, with 3 million shares allocated for public offering in Hong Kong and 27 million shares for international offering [2] - The expected net fundraising amount is approximately HKD 1.058 billion, with funds allocated for expanding production capacity in Thailand and China, as well as for operational purposes [2][4] Group 2 - Guoen Technology specializes in new chemical materials and collagen products, serving the chemical and health industries, focusing on R&D, production, and sales [4] - The company ranks second in the organic polymer modification and composite materials industry in China by sales revenue, with a market share of 2.5%, and is the largest producer of polystyrene in China [4] - In the health sector, Guoen Technology's subsidiary, Dongbao Biological, has established a complete layout from collagen raw materials to end products, becoming a comprehensive group in the health segment [4] Group 3 - For the fiscal years 2022 to 2024, Guoen Technology's revenues were RMB 13.406 billion, RMB 17.439 billion, and RMB 19.188 billion, with corresponding profits of RMB 0.724 billion, RMB 0.540 billion, and RMB 0.721 billion [5] - The company has shown solid performance in its financial results, indicating a stable growth trajectory [5]